Phase 1 × NIH × Sorafenib × Clear all
NCT01159301 2013-09-19

Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1 Terminated
44 enrolled
NCT00131989 2013-01-09

Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 1 Completed
48 enrolled
NCT00118170 2013-01-07

Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function

National Cancer Institute (NCI)

Phase 1 Completed
150 enrolled